Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Genenta Science SpA, a clinical-stage biotechnology company, is dedicated to the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company is headquartered in Milan, Italy.
52W High
$7.28
52W Low
$2.74
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.62
Valuation
As of 2024-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-11.48
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
4.39
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
39.15%
Institutions (25–75% balanced)
10.74%
Shares Outstanding
18,289,900
Float
11,223,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2024-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.57
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.54%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.1736
Previous
-0.1385
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025